ArticleBMC cancer2026
Clinical factors are more strongly associated with prognosis than genetic alterations in early-onset colorectal cancer: a retrospective cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly-onset colorectal cancer (EOCRC) is increasing globally and exhibits both aggressive clinicopathological features and distinct molecular characteristics. However, the relative contribution of clinical and genetic factors to prognosis remains unclear, particularly in underrepresented populations.
methodsA retrospective cohort study was conducted on 100 colorectal cancer (CRC) patients under 50 years of age, diagnosed and treated between January 2016 and December 2020, with follow-up up to 60 months or until death. Patients were stratified by patient characteristics, oncological features, and genetic mutation status to perform overall survival (OS) analysis.
resultsThe mean OS was 49.8 months (95% CI: 46.4-53.2), with an estimated 5-year OS rate of 65.2%. The mean disease-free survival (DFS) was 50.1 months (95% CI: 46.2-53.9). In univariate analysis, factors significantly associated with OS included serum CEA level at diagnosis (p = 0.001), histological grade (p = 0.006), mode of surgery (emergency vs. elective) (p = 0.003), curative resection status (p < 0.001), disease stage (p < 0.001), mutations in the POL-MMR DNA repair gene group (p = 0.035), high mutation accumulation (p = 0.020), PIK3CA mutation (p = 0.036), and co-mutation of RAS/RAF and MMR genes (p = 0.011). However, when adjusted for disease stage, only patient and oncological factors remained associated with OS, including elevated CEA (HR = 2.33, 95% CI: 1.2-4.7, p = 0.018), poorly differentiated tumors (HR = 2.57, 95% CI: 1.2-5.7, p = 0.021), emergency surgery (HR = 3.50, 95% CI: 1.5-7.9, p = 0.003), and curative treatment (HR = 0.10, 95% CI: 0.05-0.2, p < 0.001).
conclusionIn EOCRC, clinical and treatment-related factors remained independently associated with overall survival after adjustment for disease stage, whereas the evaluated genetic variables did not retain statistical significance. These findings highlight the importance of clinical management strategies, while the prognostic value of genetic alterations requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.